80099-88-3Relevant articles and documents
EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS
-
Paragraph 0100-0101, (2020/08/21)
The present invention relates to novel compounds of formula I, or pharmaceutically acceptable salts, solvates or stereoisomers thereof, also to a pharmaceutical composition, a method for inhibiting biological activity of epidermal growth factor receptor (
Preparation 2-substituted-4-pyridylzinc bromides via direct insertion of active zinc and their coupling reactions
Shin, Ueon Sang,Cho, Kyung-Hwan,Kim, Seung-Hoi
, p. 1575 - 1578 (2013/07/28)
-
Novel aryl- and heteroarylpiperazines
-
Page 32, (2008/06/13)
Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.